Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 3/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.44 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244152 | 0.86 | TAAR1 (0.53) | PTPN7DUSP3NR3C2ARTAAR1 | |
| Hydrochloric Acid SCHEMBL3230959 | 0.84 | TAAR1 (0.52) | PTPN7DUSP3NR3C2ARTAAR1 | |
| SCHEMBL18266749 | 0.84 | LOXL2 (0.40) | PTPN7DUSP3ARLOXL2LOX | |
| SCHEMBL297408 | 0.83 | KIF11 (0.53) | LOXL2LOXTAAR1KIF11MAOB | |
| SCHEMBL30139652 | 0.83 | KIF11 (0.53) | LOXL2LOXTAAR1KIF11MAOB | |
| SCHEMBL8690013 | 0.83 | LOXL2 (0.47) | LOXL2LOXTAAR1IDO1KIF11 | |
| SCHEMBL10662203 | 0.83 | PTPN7 (0.47) | PTPN7DUSP3NR3C2AREPHX1 | |
| SCHEMBL297428 | 0.82 | NR3C2 (0.48) | PTPN7DUSP3NR3C2AREPHX1 | |
| SCHEMBL12459224 | 0.82 | LOXL2 (0.41) | PTPN7DUSP3ARLOXL2LOX | |
| SCHEMBL4369986 | 0.81 | ST14 (0.55) | ARLOXL2LOXMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | KUKJE PHARMA CO., LTD. (KR) | 2025-11-11 | — | — | US | disclosed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025042797-A1 | TRIM7 INHIBITORS AND USES THEREOF | SHATTUCK LABS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-114302874-B | Indole carboxamide derivatives and pharmaceutical compositions containing the same | 国际药品株式会社 | 2025-02-25 | — | — | CN | disclosed |
| US-20250049791-A1 | Synthesis of MEK7 Inhibitors and methods of Use Thereof | NORTHWESTERN UNIVERSITY | 2025-02-13 | — | — | US | disclosed |
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3626718-B1 | FIVE-MEMBERED-FUSED-SIX-MEMBERED AZA-AROMATIC RING COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | UNIV XIAMEN (CN) | 2024-05-15 | — | — | EP | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| US-6545023-B2 | For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-6514965-B1 | For treating bacterial infections | ANTEX PHARMA INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1229913-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2002013824-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| WO-2001035964-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR1, CCRL2, CCR5 | PTPN7 1603/4885DUSP3 3243/4885NR3C2 219/4885 |
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | PTGES, PTGES2, PTGS1 | PTPN7 3957/4885DUSP3 2802/4885NR3C2 766/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | PTPN7 603/4885DUSP3 2892/4885NR3C2 2/4885 |
| US-20250049791-A1 | Synthesis of MEK7 Inhibitors and methods of Use Thereof | MAPK7, MAP3K7, NRAS | PTPN7 207/4885DUSP3 293/4885NR3C2 2370/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | PTPN7 4049/4885DUSP3 1396/4885NR3C2 624/4885 |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | AKR1C2, AKR1B1, AKR1C1 | PTPN7 4049/4885DUSP3 1396/4885NR3C2 624/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | PTPN7 4049/4885DUSP3 1396/4885NR3C2 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.